Limited information is available on the impact of the COVID-19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres throughout Italy during the pandemic between February 2020 and January 2021. Within this cohort, we recorded 217 SARS-CoV-2-positive patients (2·5%). Most patients (57%) were diagnosed as having SARS-CoV-2 infection during the second peak of the pandemic (September 2020 to January 2021). The majority (35%) was aged between 50 and 65 years with a male prevalence (73%). Fifty-six percent of patients presented concomitant comorbidities. The median time from CML diagnosis to SARS-CoV-2 infection was six years (three months to 18 years). Twenty-one patients (9·6%) required hospitalization without the need of respiratory assistance, 18 (8·2%) were hospitalized for respiratory assistance, 8 (3·6%) were admitted to an intensive care unit, while 170 (78%) were only quarantined. Twenty-three percent of patients discontinued tyrosine kinase inhibitor (TKI) therapy during the infection. Twelve patients died due to COVID-19 with a mortality rate of 5·5% in the positive cohort and of 0·13% in the whole cohort. We could also document sequelae caused by the SARS-CoV-2 infection and an impact of the pandemic on the overall management of CML patients.

Breccia, M., Abruzzese, E., Accurso, V., Attolico, I., Barulli, S., Bergamaschi, M., Binotto, G., Bocchia, M., Bonifacio, M., Caocci, G., Capodanno, I., Castagnetti, F., Cavazzini, F., Crisà, E., Crugnola, M., De Candia, M., Elena, C., Fava, C., Galimberti, S., Gozzini, A., Gugliotta, G., Intermesoli, T., Iurlo, A., La Barba, G., Latagliata, R., Crescenzi, S., Levato, L., Loglisci, G., Lucchesi, A., Luciano, L., Lunghi, F., Luzi, D., Malato, A., Miggiano, M., Pizzuti, M., Pregno, P., Rapezzi, D., Rege-Cambrin, G., Rosti, G., Russo, S., Sancetta, R., Scortechini, A., Sora', F., Sportoletti, P., Stagno, F., Tafuri, A., Tiribelli, M., Foà, R., Saglio, G., COVID-19 infection in chronic myeloid leukemia after one year of the pandemic in Italy Campus CML report, <<BRITISH JOURNAL OF HAEMATOLOGY>>, 2022; 196 (3): 559-565. [doi:10.1111/bjh.17890] [http://hdl.handle.net/10807/217951]

COVID-19 infection in chronic myeloid leukemia after one year of the pandemic in Italy Campus CML report

Sora', Federica;
2022

Abstract

Limited information is available on the impact of the COVID-19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres throughout Italy during the pandemic between February 2020 and January 2021. Within this cohort, we recorded 217 SARS-CoV-2-positive patients (2·5%). Most patients (57%) were diagnosed as having SARS-CoV-2 infection during the second peak of the pandemic (September 2020 to January 2021). The majority (35%) was aged between 50 and 65 years with a male prevalence (73%). Fifty-six percent of patients presented concomitant comorbidities. The median time from CML diagnosis to SARS-CoV-2 infection was six years (three months to 18 years). Twenty-one patients (9·6%) required hospitalization without the need of respiratory assistance, 18 (8·2%) were hospitalized for respiratory assistance, 8 (3·6%) were admitted to an intensive care unit, while 170 (78%) were only quarantined. Twenty-three percent of patients discontinued tyrosine kinase inhibitor (TKI) therapy during the infection. Twelve patients died due to COVID-19 with a mortality rate of 5·5% in the positive cohort and of 0·13% in the whole cohort. We could also document sequelae caused by the SARS-CoV-2 infection and an impact of the pandemic on the overall management of CML patients.
2022
Inglese
Breccia, M., Abruzzese, E., Accurso, V., Attolico, I., Barulli, S., Bergamaschi, M., Binotto, G., Bocchia, M., Bonifacio, M., Caocci, G., Capodanno, I., Castagnetti, F., Cavazzini, F., Crisà, E., Crugnola, M., De Candia, M., Elena, C., Fava, C., Galimberti, S., Gozzini, A., Gugliotta, G., Intermesoli, T., Iurlo, A., La Barba, G., Latagliata, R., Crescenzi, S., Levato, L., Loglisci, G., Lucchesi, A., Luciano, L., Lunghi, F., Luzi, D., Malato, A., Miggiano, M., Pizzuti, M., Pregno, P., Rapezzi, D., Rege-Cambrin, G., Rosti, G., Russo, S., Sancetta, R., Scortechini, A., Sora', F., Sportoletti, P., Stagno, F., Tafuri, A., Tiribelli, M., Foà, R., Saglio, G., COVID-19 infection in chronic myeloid leukemia after one year of the pandemic in Italy Campus CML report, <<BRITISH JOURNAL OF HAEMATOLOGY>>, 2022; 196 (3): 559-565. [doi:10.1111/bjh.17890] [http://hdl.handle.net/10807/217951]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/217951
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 20
social impact